ArticleProgress in rehabilitation medicine2026
Prognostic Value of the Kihon Checklist in Older Cardiovascular Disease Patients.
Article in Progress in rehabilitation medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Of various frailty indicators, none are suitable for cardiovascular disease (CVD). We aimed to verify the association between the Kihon checklist (KCL) score and prognosis of older adults with CVD. Methods: Participants (n = 336) were adults with CVD (aged ≥ 65 years, mean age 81 years) who required hospitalization. They were assessed with the KCL, and data were obtained for left ventricular ejection fraction (LVEF) and brain natriuretic peptide (BNP) at discharge, and the occurrence of all-cause death, CVD composite endpoint, CVD death, and CVD hospitalization after discharge. The cutoff value of the KCL score for all-cause death was calculated using receiver operating characteristic analysis, and participants were divided into two groups. The relationship between KCL score and prognosis was examined using survival time (Kaplan-Meier method) and Cox proportional hazards analyses. Results: The KCL cutoff value was 8 (KCL < 8, n=155). Survival time analysis showed significant differences in all-cause death, CVD composite endpoint, and CVD death (log-rank test: P < 0.001, each). Cox proportional hazards analysis showed that KCL score of 8 or higher was significantly associated with all-cause death [hazard ratio (HR), 2.731; 95% confidence interval (CI), 1.202-6.205] and CVD death (HR, 2.875; 95% CI, 1.124-7.353). In the HF only group, KCL score of 8 or higher was not significantly associated with all-cause death, CVD death, or CVD composite endpoint. Conclusions: Total KCL score was associated with mortality in the overall cohort of older adults with CVD, although the association in the HF subgroup alone showed a borderline trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.